Secondary Cytoreductive Surgery in Platinum-resistant Recurrent Ovarian Cancers
Status:
Recruiting
Trial end date:
2023-03-30
Target enrollment:
Participant gender:
Summary
This novel study was specifically designed for platinum resistant recurrent ovarian cancers
and aimed to compare cases who received secondary cytoreductive surgery for isolated
recurrence and chemotherapy versus chemotherapy alone. This comparison will conduct the
intraoperative events, postoperative morbidity and mortality, pathological outcomes and
long-term oncological outcomes as regarding progression free survival and overall survival
rates.